Showing results (261-270 of 296) with videos related to

Sort By:
Pageof 30
Multiple Sclerosis and Related Disorders|February 20, 2026
Abuse in individuals with multiple sclerosis: the SocialMS Italian studyMarta Ponzano, Alessio Signori, Irene Schiavetti, et al.
Immunotherapy|January 20, 2025
Role of Hb to RDW ratio in metastatic renal cell carcinoma patients treated with first-line immunotherapy combinationsMatilde Corianò, Alessandro Lazzarin, Michele Maffezzoli, et al.
Cancers|April 12, 2022
Prognostic Value of the BIO-Ra Score in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Radium-223 after the European Medicines Agency Restricted Use: Secondary Investigations of the Multicentric BIO-Ra StudyMatteo Bauckneht, Sara Elena Rebuzzi, Marta Ponzano, et al.
Journal of the Neurological Sciences|May 15, 2025
Safety assessment of switching from fingolimod to siponimod: An Italian multicenter prospective studyGianmarco Abbadessa, Irene Schiavetti, Luca Bollo, et al.
Multiple Sclerosis and Related Disorders|May 8, 2024
NEDA-3 achievement in early highly active relapsing remitting multiple sclerosis patients treated with Ocrelizumab or NatalizumabElisabetta Signoriello, Alessio Signori, Giacomo Lus, et al.
Frontiers in Immunology|July 22, 2024
Sodium levels and immunotherapy efficacy in mRCC patients with bone metastases: sub analysis of Meet-Uro 15 studyMartina Catalano, Sara Elena Rebuzzi, Marco Maruzzo, et al.
JAMA Network Open|November 27, 2023
Sodium Levels and Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving NivolumabMartina Catalano, Sara Elena Rebuzzi, Marco Maruzzo, et al.
European Journal of Neurology|September 24, 2021
A real-world study of alemtuzumab in a cohort of Italian patientsCinzia Valeria Russo, Francesco Saccà, Jessica Frau, et al.
Journal of Clinical Medicine|July 2, 2021
Tracheostomy Timing and Outcome in Severe COVID-19: The WeanTrach Multicenter StudyDenise Battaglini, Francesco Missale, Irene Schiavetti, et al.
Cancer Immunology, Immunotherapy : CII|July 2, 2024
Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of meet-URO15 studyCarlo Messina, Martina Catalano, Giandomenico Roviello, et al.
Pageof 30